Autoantibodies against p53, MMP-7, and Hsp70 as Potential Biomarkers for Detection of Nonmelanoma Skin Cancers. (12th July 2021)

• Record Type: Journal Article
• Authors: Yang, Shi-Han; Liu, Can-Tong; Hong, Chao-Qun; Huang, Ze-Yuan; Wang, Huan-Zhu; Wei, Lai-Feng; Lin, Yi-Wei; Guo, Hai-Peng; Peng, Yu-Hui; Xu, Yi-Wei
• Other Names: Simonsen Anja Hviid Academic Editor.
• Is Part Of: Disease markers. Volume 2021(2021)
• Publication Date: 2021-07-12
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2021/5592693
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are two predominant histological types of nonmelanoma skin cancer (NMSC), lacking effective early diagnostic markers. In this study, we assessed the diagnostic value of autoantibodies against p53, MMP-7, and Hsp70 in skin SCC and BCC. ELISA was performed to detect levels of autoantibodies in sera from 101 NMSC patients and 102 normal controls, who were recruited from the Cancer Hospital of Shantou University Medical College. A receiver operator characteristic curve was used to evaluate the diagnostic value. The serum levels of autoantibodies against p53, MMP-7, and Hsp70 were higher in NMSCs than those in the normal controls (all P < 0.01 ). The AUC of the three-autoantibody panel was 0.841 (95% CI: 0.788-0.894) with the sensitivity and specificity of 60.40% and 91.20% when differentiating NMSCs from normal controls. Furthermore, measurement of this panel could differentiate early-stage skin cancer patients from normal controls (AUC: 0.851; 95% CI: 0.793-0.908). Data from Oncomine showed that the level of p53 mRNA was elevated in BCC (P < 0.05 ), and the Hsp70 mRNA was upregulated in SCC (P < 0.001 ). This serum three-autoantibody panel might function in assisting the early diagnosis of NMSC.